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Abstract
Inflammatory bowel diseases (IBD), including ulcerative 
colitis and Crohn’s disease are chronic, life-long, 
and relapsing diseases of the gastrointestinal tract. 
Currently, there are no complete cure possibilities, 
but combined pharmacological and nutritional therapy 
may induce remission of the disease. Malnutrition 
and specific nutritional deficiencies are frequent 
among IBD patients, so the majority of them need 
nutritional treatment, which not only improves the 
state of nutrition of the patients but has strong 
anti-inflammatory activity as well. Moreover, some 
nutrients, from early stages of life are suspected as 
triggering factors in the etiopathogenesis of IBD. Both 
parenteral and enteral nutrition is used in IBD therapy, 
but their practical utility in different populations and in 
different countries is not clearly established, and there 
are sometimes conflicting theories concerning the role 
of nutrition in IBD. This review presents the actual data 
from research studies on the influence of nutrition on 
the etiopathogenesis of IBD and the latest findings 
regarding its mechanisms of action. The use of both 
parenteral and enteral nutrition as therapeutic methods 
in induction and maintenance therapy in IBD treatment 
is also extensively discussed. Comparison of the latest 
research data, scientific theories concerning the role 
of nutrition in IBD, and different opinions about them 
are also presented and discussed. Additionally, some 
potential future perspectives for nutritional therapy are 
highlighted.
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Core tip: Inflammatory bowel diseases (IBD), including 
ulcerative colitis and Crohn’s disease are chronic, life-
long, and relapsing diseases of the gastrointestinal 
tract. Currently, there are no complete cure possibilities, 
but combined pharmacological and nutritional therapy 
may induce remission of the disease. Both parenteral 
and enteral nutrition is used in IBD therapy, but their 
practical utility is not clearly established, and the 
evidence is sometimes conflicting. This review presents 
the latest findings of research studies regarding 
the influence of nutrition on the etiopathogenesis 
of IBD, its mechanisms of action, and its use as a 
therapeutic method. Additionally, some potential future 
perspectives for nutritional therapy are highlighted.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a collection of 
chronic inflammatory disorders of the gastrointestinal 
tract, including ulcerative colitis (UC) and Crohn’s disease 
(CD), which is characterized by periods of remission 
and flare-up of the disease[1]. The inflammatory process 
observed in UC is continuous and limited to the mucosa 
of the colon, while in contrast; CD is characterized by 
transmural inflammation and skip lesions, located in any 
region of the gastrointestinal tract[2]. Both CD and UC, 
despite multiple differences, share similar symptoms, 
including abdominal pain, diarrhea, extraintestinal 
manifestations, and malnutrition[1,2].
The pathogenesis of malnutrition in IBD is mul-
tifactorial. Chronic nutrition deficiencies are probably 
secondary to inadequate calorie intake and increased 
energy expenditure during chronic and relapsing 
inflammatory lesions[3]. In addition, pharmacological and 
surgical treatment may impair digestion and absorption 
of nutrients because of different drug-nutrient inter-
actions and reduced absorptive area of the intestine 
secondary to surgical resections[4]. Nevertheless, 
direct inhibitory effects of pro-inflammatory mediators 
secreted from the inflamed tissue are also very im-
portant for the state of malnutrition[2].
The management of IBD includes pharmacological, 
nutritional, and surgical therapy. The main goal of the 
treatment is induction and maintenance of remission, 
correction of nutritional deficiencies, and prevention of 
complications[1].
Nutritional therapy may be carried out through 
enteral (EN) or parenteral nutrition (PN). Moreover, 
nutritional treatment can be divided into primary and 
support therapy. The aim of the first is to induce and 
maintain remission and the second to support the 
long-lasting effects of drug therapy[4]. PN may be an 
alternative method of nutrition to enteral intake of 
nutrients in IBD patients, mainly used for those with 
contraindications or EN intolerance, especially when 
there are symptoms of severe malnutrition. Total 
parenteral nutrition (TPN) may be also used during 
the acute inflammatory phase (obstruction, toxic 
megacolon, and active fistulas) in the preoperative 
period and in patients with short bowel syndrome (SBS) 
due to previous extensive bowel resections[5,6].
Indications for EN in the treatment of IBD include 
exclusive enteral nutrition (EEN) for active disease, 
supplemental EN to maintain disease remission, and 
nutritional support to achieve adequate weight gain 
and growth[4]. Treatment by EN is more effective in 
achieving clinical remission in children with IBD than 
in adults[7,8]. Recent meta-analysis of clinical trials 
indicated that the efficacy of EEN might be comparable 
to that of corticosteroid therapy[9]. EEN decreases 
disease activity and promotes mucosal healing in 
patients with IBD, but the mechanism of action of this 
therapy is still poorly understood.
DIETARY FACTORS IN THE ETIOLOGY 
OF IBD
It is well known that the molecular basis of IBD is 
linked with the immunology of T-cells. Most popular 
theories suggest that T cells are activated due to a 
confluence of genetic and environmental factors, 
which generate an immune imbalance, leading to the 
inflammation characteristic of these diseases (Figure 
1)[10]. The connection of improper activation of T-cells 
with diet or diet-related factors is still not a well-
established theory. Several dietary risk factors have 
been suggested from the early beginning of life.
Breastfeeding
Several recent studies showed a protective role of 
breastfeeding against the risk of IBD. A New Zealand 
study with a relatively large group of participants 
indicated that breastfeeding has a protective effect 
against IBD [CD odds ratio (OR) = 0.55 (0.41-0.74), 
UC OR = 0.71 (0.52-0.96)] with a duration-response 
effect[11]. Many studies limit those beneficial effects 
to subjects with at least 6 mo of nursing. Slovak 
studies established that breastfeeding for less than 
6 mo was a risk factor for both CD (OR = 2.7) and 
UC (OR = 1.7)[12]. In a Danish study, breastfeeding 
for more than 6 mo decreased the odds for IBD 
(OR = 0.50; 95%CI: 0.23-1.11)[13]. However, some 
giant multicenter studies did not support these 
findings - in an extremely large study (but in women 
only), no significant association was found between 
breastfeeding and IBD in adulthood[14,15]. Conversely, 
a meta-analysis found a significant protective effect of 
breastfeeding (OR = 0.69, 95%CI: 0.51-0.94) against 
the development of IBD in pediatric patients[16]. An 
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older meta-analysis, based mainly on studies from 
the previous century, found that breastfeeding had a 
protective effect on the development of UC (OR = 0.61, 
95%CI: 0.44-0.84) but not CD[17]. The mechanism 
by which breastfeeding protects against IBD is not 
precisely known. Feeding in the first months of life is 
crucial for the development of gut microflora. The gut 
microbiome stimulates innate and acquired immunity, 
promotes the maturation of the mucosal immune 
system and the integrity of the mucosa, and develops 
tolerance to food antigens as well[18,19]. Some authors 
assign a special role in this process to lactoferrin[20]. 
This peptide, present in human milk only (absent in 
formula), possesses anti-inflammatory, antibacterial, 
and antiviral properties[21].
Carbohydrates in the diet 
Several Danish studies showed that a high intake of 
digestible sugar increased the risk of total IBD [OR = 
2.5 (1.0-6.2)] and CD [OR = 2.9 (1.0-8.5)][13,22]. In 
an older study, only high sucrose consumption was 
associated with an increased risk for IBD (OR = 2.85, 
p = 0.03). The EpiCom cohort (1560 IBD patients 
from 31 European countries) study revealed that 
increased sugar consumption and daily fast food were 
associated with earlier onset of IBD and an increased 
risk of disease severity and surgery in UC[23]. A more 
detailed study showed that lactose consumption 
has no effect, while fructose intake was negatively 
associated with risk for IBD[24]. Some foodstuffs, such 
as bread, are difficult to categorize correctly, thus the 
results of such studies can be contradictory. In one 
study, high bread intake was protective against IBD 
- [OR = 0.42 (95%CI: 0.26-0.70)][13], while another 
study delivered quite the opposite result - high bread 
intake increased risk of IBD onset (RR = 6.38)[25]. A 
detailed study showed that frequent intake of white 
bread [OR = 4.9 (95%CI: 1.0-23.4, p = 0.05)] was 
associated with an increased risk of CD onset and that 
a diet rich in non-digestible fibers, like vegetable and 
whole meal bread, is protective against IBD [CD: 0.3 
(0.1-1.0)], UC [0.3 (0.1-0.8)]; OR: 0.5 (0.3-0.9), CD 
[0.4 (0.2-0.9) respectively][22]. However, another study 
found that high fiber diet was protective against the 
risk of CD but not UC[26]. Fiber has anti-inflammatory 
properties as well and positively modulates the internal 
microbiome[18]. Fibers are fermented by colonizing 
bacteria into short chain fatty acids. These fatty acids 
activate peroxisome proliferator-activated receptor γ, 
a nuclear transcription factor with anti-inflammatory 
effects[27]. Digestible sugars in the diet modify the 
intestinal microbiome, increasing the prevalence of 
prevotella, whereas protein and animal fat in the diet 
cause an increase in Bacteroides[28].
Starch, one of the most important carbohydrates 
present in the human diet, strongly influences the 
microbiome as well. It is a necessary substrate 
for intestinal bacteria, especially to promote the 
development of Klebsiella microbes[29]. Because 
the levels of anti-Klebsiella antibodies were high in 
CD patients, it has been theorized that Klebsiella 
species are an important factor in the induction of 
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Figure 1  Sequence of events of inflammatory process in the gut.
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incidence of colitis was markedly increased in milk fat-
fed interleukin (IL)-10-deficient mice but not in normal 
mice or polyunsaturated fat-fed IL-10-deficient mice. 
Bilophila wadsworthi was observed in the feces of milk 
fat-fed mice, indicating dysbiosis[40]. This finding was 
clearly linked with taurine conjugation of hepatic bile 
acids by Bilophila wadsworthi, with direct evidence 
showing that IL-10-deficient mice fed a low-fat diet 
containing taurocholic acid, but not glycocholic acid, 
developed colitis[41].
Proteins and allergens
The role of protein consumption in IBD etiology is 
controversial. In a French study, high total protein 
intake, specifically animal protein, was associated 
with a significantly increased risk of IBD in future 
life (hazards ratio for the third vs first tertile and 
95% confidence interval being 3.31 and 1.41-7.77 
(p trend = 0.007) and 3.03 and 1.45-6.34 (p trend 
= 0.005) for total and animal protein, respectively). 
High consumption of meat or fish was suspected as 
a risk factor, but high consumption of eggs or dairy 
products was not[42]. A German twin study indicated 
that high consumption of processed meat, including 
sausage, was associated with an increased risk of CD 
(OR = 7.9, 95%CI: 2.15-38.12 - monozygotic twins 
OR = 10.75, 95%CI: 4.82-25.55 - dizygotic twins) 
as well as UC (OR = 5.69, 95%CI: 1.89-19.48; OR 
= 18.11, 95%CI: 7.34-50.85; mono and di-zygotic 
twins respectively)[43]. Some papers have documented 
similar relationships in Japan, where increased intake 
of dairy products and meat accompanied the rising 
trend of UC[44]. One of the promising explanations of 
this phenomenon is allergy to cow’s milk proteins. In 
recent studies it was shown that allergy to cow’s milk 
protein at infancy was associated with CD (OR = 1.92, 
95%CI: 1.09-3.36, p < 0.05) and UC (OR = 1.71, 
95%CI: 1.04-2.83, p < 0.05) in later childhood[45]. 
An alternative explanation may be connected with 
Mycobacterium avium subspecies paratuberculosis 
(MAP) infection, which is strongly suspected in the 
pathogenesis of multiple diseases, including IBD[46,47]. 
MAP is broadly distributed in the environment, water, 
and food. Some nutrients, such as milk, meat and 
sugar, may fortify its invasiveness[48,49].
Micronutrients and vitamins
Magnesium (p = 0.04), vitamin C, and fruits were 
negatively associated with risk for IBD, while a positive 
association was found for retinol (p = 0.01). Potassium 
intake and vegetable consumption showed a negative 
association only with risk for CD[24]. Experiments in 
animal models indicated a significant role for selenium 
shortage in the pathogenesis of IBD, as it is a cofactor 
of anti-inflammatory proteins[50], but no correlation 
was found in the case of folate[51]. Vitamin D is also 
significant in IBD development. Data obtained in a 
mouse model of colitis demonstrated that 1,25(OH)2D3 
autoimmunological reactions through the mechanism 
of molecular mimicry. Furthermore, strong positive 
correlation and cross-reactive antibodies were observed 
between Klebsiella and collagen in CD and ankylosing 
spondylitis patients[30]. Additionally, the “low starch diet” 
used in ankylosing spondylitis patients decreased the 
level of inflammatory mediators and reduced the clinical 
symptoms of disease[31].
Recently, interesting studies regarding the use of 
the “specific carbohydrate diet” (SCD) in CD children 
were published. SCD, initially used in celiac disease 
treatment almost 70 years ago, contains almond, nut, 
and coconut flours and excludes grains (wheat, rice, 
corn). Additionally, the majority of dairy products are 
restricted, except fermented yogurt, and the only sugar 
allowed is fructose (honey). Two small, independent 
United States retrospective studies that assessed 
SCD as the sole method of treatment in CD children 
showed that the use of SCD for 5 to 30 (or 12 to 52, 
respectively) months had positive effects on laboratory 
inflammatory markers and clinical presentation of the 
disease, including mucosal healing[32,33]. The direct 
reason for the improvement was not known, but 
modification of the intestinal microbiome was the most 
probable cause. Nevertheless, prospective studies are 
necessary to confirm these preliminary results.
Fat in the diet
It has been known for years that high animal fat intake 
is associated with an increased risk for UC (OR = 4.09, 
p = 0.02) as is cholesterol intake (OR = 4.57, p = 
0.02)[24]. In another study, high consumption of mono- 
and disaccharides and total fats consistently increased 
the risk for CD and UC[34]. Several studies showed that 
prolonged, habitual intake of fast food, commonly rich 
in fats and digestible sugars, is a risk factor for CD[23].
Significant attention has been paid to the role of 
unsaturated fatty acids in the pathogenesis of IBD. A 
diet rich in olive oil and fish, but also in vegetables, 
fruits, grains, and nuts, was inversely associated with 
CD in both genders (girls: OR = 0.3, 95%CI: 0.1-0.9; 
boys: OR = 0.2, 95%CI: 0.1-0.5)[35]. Increased 
intake of ω-6 polyunsaturated fatty acids (PUFA, 
beef, pork, corn, sunflower oils, and polyunsaturated 
margarines) in place of ω-3 PUFA (fish) was associated 
with an increased incidence of IBD[36,37]. High intakes 
of ω-6 PUFA linoleic acid were associated with a 
greater risk of developing UC (p = 0.01; OR = 2.49, 
95%CI: 1.23-5.07 for the highest quartile) in a dose-
dependent manner (p = 0.02). This association was 
observed in both genders, but it was significant only in 
women (p = 0.03). On the other hand, high intakes of 
the ω-3 PUFA docosahexaenoic acid were associated 
with lower risks of developing UC (p = 0.03)[38]. The 
action of saturated and unsaturated fats could be 
realized through modulation of Toll-like receptors in 
macrophages[39].
Some evidence linked fat intake with dysbiosis. The 
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or vitamin D receptor deficiency caused dysbiosis, 
leading to increased susceptibility to gastrointestinal 
injury[52]. On the other hand, increased intake of 
vitamin D protected against IBD in an animal model 
and in humans, but only against CD[53,54].
Preservatives and additives in foodstuffs
Increased dietary sulfur is a result of its use as a 
preservative food additive[55]. This additive is linked 
with an increased number of UC cases[56], and it 
is suggested that sulfur may be toxic to human 
colonocytes following its metabolism by colonic bacteria 
to hydrogen sulfide (H2S)[57]. The polysaccharide 
dietary additive maltodextrin was shown to impair 
cellular anti-bacterial responses and suppress intestinal 
anti-microbial defense mechanisms, which could result 
in IBD onset[58].
Microparticles, such as titanium dioxide, aluminum 
silicates, and talc, can act as antigen transporters 
from the intestinal lumen to the mucosa and have 
been linked with the development of CD[59]. Aluminum 
silicates are used as a co-compound of anti-acids, and 
sodium aluminosilicate and talc (E-553b) are added to 
powdered foods to prevent lump formation. Titanium 
dioxide is a food and toothpaste colorant (E171). 
These microparticles are absorbed by the specialized 
M cells but are undegradable and accumulate in 
macrophages and lymphoid tissue and induce the 
secretion of proinflammatory IL-1β and IL-18[60]. As 
adjuvants facilitate the interactions of mucosa with 
antigens, they impair the local immune system[61]. 
Many others substances from toothpaste are suspected 
to be linked to IBD etiology. Tricalcium phosphate and 
quartz (abrasives) in animal models penetrated the 
epithelium and created enteric lesions similar to those 
in Crohn’s disease. Also carrageenans, widely used in 
foodstuffs and toothpastes for their gelling, thickening, 
and stabilizing properties, injured enterocytes in animal 
models, in a manner typical of IBD in humans[62].
Beverages 
A high intake of fluids (p = 0.04) was negatively 
associated with the risk of IBD[24]. Furthermore, green 
tea and coffee reduce the risk of IBD in Asian and 
Australian populations. Daily tea consumption was 
associated with a reduced risk of CD (aOR = 0.62; 
95%CI: 0.43-0.91), whereas both daily tea (aOR = 
0.63; 95%CI: 0.46-0.86) and coffee consumption (aOR 
= 0.51; 95%CI: 0.36-0.72) were associated with a 
reduced risk of UC. Caffeine ameliorated acute colitis in 
intestinal epithelial cells in an in vitro study[63]. Green 
tea is rich in polyphenols - antioxidants that attenuate 
the severity of colitis in an animal model[64]. A similar 
protective mechanism is postulated in the case of 
wine consumption[65]. However, wine also contains 
sulfur dioxide, which acts as a potential negative 
factor[66]. Diet and beverages are a major modifiable 
influence of the microbiome but are also a source of 
microorganisms. Water was found to be the route of 
transmission of several pathogens linked with IBD, 
such as in the potentially protective role of Helicobacter 
pylori infection against IBD[67,68].
In summary, conflicting data likely arise from 
different study designs. Some studies were retrospec-
tive, others prospective. Retrospective studies are 
burdened with errors associated with memory, and 
prospective studies have biases based on some social 
issues, such as modification of answers to fit with 
promoted healthy lifestyle standards[69]. Another 
possible source of bias is connected with different 
groups of patients (children vs adults and different 
genders, different races), small sample sizes, and 
heterogeneity of disease subtypes. In addition, type 
of food vs nutrients results in severe inconsistencies 
between studies[70]. For instance, the influence of fruits 
and vegetables on IBD onset is multifactorial, as they 
are a source of digestible sugars, fiber, microelements, 
vitamins, and proteins but also potential allergens. 
They may also carry some preservatives, depending 
on the country of origin. Therefore, it is impossible to 
consistently interpret the results of all of these different 
studies. 
ROLE OF NUTRITION IN IBD
Malnutrition
Malnutrition is common among IBD patients and can 
be recognized by protein-energy malnutrition, altered 
body composition, and micronutrient deficiencies. 
Malnutrition is one of the most important factors 
linked with poor outcome in patients with IBD[71]. The 
most common type in adult IBD patients is protein-
energy malnutrition, predominantly seen as weight 
loss[72]. In a recent Romanian study, the prevalence 
of malnutrition based on body mass index (BMI) in 
IBD patients was established as 30.6%[73]. The rate 
of patients suffering from protein-energy malnutrition 
was significantly higher among IBD patients (OR = 
5.57, 95%CI: 5.29-5.86) than it was among non-IBD 
cases, for both CD (p < 0.0001) and UC patients (p 
< 0.0001)[74]. In a Serbian study, of 76 IBD patients 
(23 CD and 53 UC), 52 (68.4%) met the criteria for 
malnourishment, and 24 (31.6% of the entire cohort) 
were severely malnourished[75]. A similar situation was 
observed in children - up to 60% of newly diagnosed 
CD children - but only 35% of patients with UC present 
symptoms of malnutrition[76].
An unexpected high proportion of patients with 
IBD (mostly UC patients) are overweight[77]. A recent 
Untied States study showed that obesity prevalence 
in IBD patients reflects the obesity index in the 
general population[78]. A very promising observation 
is that clinical outcomes in obese patients are better 
than in non-obese patients with IBD, and obesity 
(defined using BMI index) is a marker of a less severe 
disease course in IBD[78]. A relatively high percentage 
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of obese patients during diagnosis could be related 
to an increase in obesity in the general population, 
accompanied by earlier IBD recognition. 
IBD sometimes develops in patients treated pre-
viously for obesity. Some surgical interventions, such as 
gastric bypass, may result in severe malnutrition in the 
case of IBD in later life[79].
There are several reasons for malnutrition and 
disturbed body composition in IBD patients (Table 
1). These factors depend on pathophysiology but 
could be superimposed with iatrogenic factors. During 
active phase of the disease, energy intake in adults 
and children is lower than in healthy controls[80]. 
Healthy siblings consume on average 1757 kJ (420 
kcal) more than their siblings with IBD (matched for 
height, sex, and weight). Imbalance is deepened 
through a higher basic metabolic rate in CD compared 
to healthy controls[81]. What is more, children with CD 
fail to adapt their resting energy expenditure to their 
diminished body mass[82]. The explanation for this 
phenomenon is based on pro-inflammatory cytokine 
action accompanying an increased lipid oxidation rate in 
CD patients[83,84]. However, diet-induced thermogenesis 
was lower in CD patients in an active compared to 
an inactive stage of disease[85]. Lack of appetite could 
be enhanced by side effects of some drugs, such as 
nausea, during methotrexate intake[86]. On the other 
hand, treatment with corticosteroids increases appetite 
but is also associated with lean mass reduction. A 
similar effect was found for mesalamine, which is 
predictive of lean mass for height Z-score less than 
-1.00[87].
Malabsorption seems to be major contributor to low 
weight in adult CD patients. Increased gastrointestinal 
nutrient losses are observed in patients after ileal 
resection or with bile acid malabsorption[88]. Bile acid 
malabsorption is common in IBD patients, whether 
the disease is localized in the ileum or not. It leads 
to malfunction of lipid digestion with steatorrhea, 
impaired intestinal motility, and/or significant changes 
in the intestinal microflora environment. Increase of fat 
in stool could also be a result of a deficit in pancreatic 
enzyme secretion. Gastric acid and pancreatic enzyme 
impaired secretion were observed in 80% of CD 
patients[89]. Loss of nutrients can also occur as a result 
of protein enteropathy from a ruptured, permeable 
gut. Studies using whole gut lavage have shown that 
disease activity closely paralleled gastrointestinal 
protein loss[90].
Several studies have documented the beneficial 
influence of therapy on total weight. In a United 
Kingdom study, 29% of children were severely 
malnourished (BMI Z-scores < -2 SD) during diagnosis 
of the CD and only 4% in UC patients. At 6 and 12 mo 
post-diagnosis, 5% and 1% of the CD children and 0% 
and 5% of UC patients had low BMI z-score values, 
respectively[84]. A similar beneficial effect of therapy 
was observed in a French study[91]. In these children, 
weight and BMI z-scores improved post-diagnosis, and 
the prevalence of CD children with low BMI (< -2 SD) 
was half of that at diagnosis.
Changes in body composition
Lean body mass: Weight and BMI are very superficial 
factors in the analysis of nutritional status. Therefore, 
profound measurements of compartments of the 
body are frequently performed. Typically, lean body 
mass in patients with IBD is lower than in the healthy 
population. A recent study showed that a decrease in 
lean mass was observed in 21% of adult patients with 
IBD[92]. In addition, a systematic review analyzing adult 
patients with IBD up to the year 2013 reported similar 
data. Independent of the methodology used, in adult 
patients with IBD, reduced fat-free mass was observed 
in 28% of CD and 13% of UC cases as compared 
to healthy controls[93]. No consistent association 
between body composition and disease activity, 
duration, extent, or therapies was found. Several 
studies showed that lean mass was also reduced 
in children with IBD compared to controls[94]. In a 
German study, significantly reduced lean mass was 
found in children with well-controlled IBD compared to 
controls [difference -0.72; 95%CI: -1.10-(-0.34)][95]. 
In a British study, fat free mass correlated negatively 
with disease activity in children with CD regardless 
of changes in weight[96]. Lean mass in CD adjusted 
for age and height was significantly lower than in 
controls. In a regression model including height, age, 
Tanner stage, and race, CD was associated with a 6% 
reduction in lean mass[97]. Only in one study, reduction 
of lean mass was predominantly observed in boys[98].
Fat mass: In a recent systematic review, fat mass 
was found not to be statistically different in 66% of 
CD patients (n = 419) and in 75% of UC patients (n 
= 220) compared to controls[93]. Thirty one percent 
of patients (n = 192) with CD and 13% of patients 
(n = 39) with CU showed a statistically significant 
reduction of fat mass. Twelve percent of patients with 
CU (n = 36) and only 3% with CD (n = 20) developed 
fat tissue better than controls - increased in 12% of 
patients compared to controls[99,100]. Another study 
Table 1  Reasons for malnutrition in inflammatory bowel 
disease patients
Reason Contributing factor
Increased nutritional 
requirements
Active inflammation
Increased nutrient losses Diarrhea, intestinal and fistulae protein 
losses
Impaired dietary intake Nausea, vomiting, loss of appetite
Nutrient malabsorption Bacterial overgrowth, secondary lactose 
malabsorption
Iatrogenic Drug - nutrient interactions, 
(drug-related, surgery-
related)
reduced intestinal absorptive area
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concluded that physical activity of adult IBD patients 
is low and correlated inversely with fat mass[101]. In 
children, some studies found no differences in fat mass 
between CD patients and control groups[102]. However, 
there are several papers describing a gender difference 
in fat mass in children with IBD. While one study 
showed that deficit of fat is predominant in girls[98], 
others reported a significantly higher percentage body 
fat in girls with CD compared to boys or to the control 
group[102,103].
Fat distribution, especially fat localized around the 
intestine lumen, is suspected to be pathognomonic as 
well as a pathogenic factor for IBD[104]. Fat deposited 
around the small or large intestine is called “fat 
wrapping”[105]. In CD, fat surrounding over 50% of 
the bowel circumference is typical[106]. Moreover, it 
is suggested that proinflammatory and modulating 
immune system adipokines secreted by this fatty tissue 
play a significant role in the disease etiopathology[107].
Bone mass: Osteopenia and osteoporosis are common 
complications of IBD and affect almost every second 
patient[108]. In a Romanian study, osteopenia was found 
in 48.07% of the patients with UC and in 56.41% of 
the patients with CD; and osteoporosis was present 
in 18.26% of the patients with UC and 15.38% of 
those with CD[109]. When examined using dual-energy 
X-ray absorptiometry (DEXA), patients with CD had 
significantly lower femoral Z scores than patients with 
UC. Femoral Z score was strongly associated with 
disease duration[110].
There are several discrepancies concerning the 
influence of age, gender, location of lesions, and BMI 
on bone mass. Early onset of IBD (before 30 years 
of age) is a risk factor for profound decrease in bone 
mineral density compared with patients diagnosed in 
old age[111]. However, age over 50 is also a risk factor 
for osteopenia and osteoporosis[112]. A recent Italian 
study showed that in newly diagnosed patients with 
IBD, osteoporosis and osteopenia were seen mostly 
in male patients over 30 years of age (63%) and in 
young women (62%)[113]. However, a similar United 
States study performed between 2008-2012 showed 
no influence of age, BMI, or disease location on bone 
mineral density[114]. Another American study noticed a 
positive correlation between bone mineral density and 
BMI[115]. Additionally, a recent Slovak study showed 
that CD patients with ileic/ileocolic location and 
history of proctocolectomy/total colectomy were at a 
higher risk of developing osteoporosis than other IBD 
patients[110].
A Canadian study using the World Health Orga-
nization Fracture Risk Assessment tool (FRAX) showed 
that IBD patients aged over 50 are at increased risk of 
hip fracture only (HR = 2.14; 95%CI: 1.26-3.65)[116]. 
Interestingly, the same authors in a similar study 
concluded that CD was associated with an increased 
risk of osteoporosis of the lumbar spine and trochanter 
only[117]. Some studies have shown an increased risk 
of vertebral fractures in children with IBD[118]. These 
observations are supported by a Swedish study that 
showed a permanent decrease in children’s BMD Z 
scores for the lumbar spine using DEXA[119]. Patients 
with a severe disease course complicated with ostomy 
and low BMD also had a five times higher frequency 
of fragility fractures than IBD patients with normal 
BMD[115].
The most popular explanation for loss of mineral 
bone matrix is malabsorption of calcium and vitamin 
D as well as treatment side effects, mainly from long-
term, systematic steroids[86,120]. Biological therapy 
is linked with better outcomes in bone mineral 
density[121]. Recent studies have linked bone mineral 
density in IBD with genetic factors[122,123]. It was also 
suggested that adipokines, as well as inflammatory 
mediators, interfere in the balance between osteoblasts 
and osteoclasts[124].
Vitamin and micronutrient deficiencies: Patients 
with IBD usually do not present overt symptoms 
of vitamin or micronutrient deficiency. The most 
detailed studies were performed on vitamin D as a 
risk factor for decreased bone mineral density. The 
conflicting results of those studies seem to depend on 
the different ethnic groups studied, living at different 
latitudes with different exposure to sunlight, different 
cut-offs for deficiency of vitamin D, and different 
methods used for vitamin measurement.
In children and adolescents from Massachusetts, 
United States, no difference was found in mean 
serum 25(OH)D concentration between IBD patients 
and healthy controls. However, patients with active 
inflammation processes confirmed by elevated 
erythrocyte sedimentation rate had significantly lower 
25(OH)D levels than controls[125]. A New Zealand study 
showed that during winter, 76% of tested IBD patients 
were vitamin D deficient (< 50 nmol/L), and all of them 
had insufficient 25(OH)D levels (< 75 nmol/L). During 
summer, only 10% of patients were deficient, but an 
insufficient level of vitamin D was still discovered in 
55% of patients. In the latter study, no relation was 
found between vitamin D deficiency and activity of 
CD[126]. Conversely, a Romanian study showed that 
vitamin D levels were significantly lower in CD patients 
with moderate to severe disease activity compared 
to CD patients in remission or with mild disease 
activity (16 ± 6 ng/mL; 26 ± 7 ng/mL; 31 ± 9 ng/mL, 
respectively)[127]. Another American study from the 
southern part of the United States (Houston) reported 
slightly lower rates of deficiency and insufficiency of 
vitamin D in a population of IBD patients, but the cut-
off was different. Insufficiency of 25(OH)D (between 
20 and 30 ng/mL) was found in 37% of IBD patients 
and deficiency (levels < 20 ng/mL) was found in 23% 
of patients. A positive correlation between low vitamin 
D status and diminished bone mineral density was also 
shown[114].
Vitamin D deficiency occurs likewise in Chinese 
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patients with UC (10.32 ± 4.46 ng/mL vs controls, p 
< 0.001) and CD patients (11.57 ± 5.02 ng/mL vs 
controls, p = 0.029) and is closely associated with 
the severity of the disease[128]. Furthermore, plasma 
25(OH)D level < 20 ng/mL was associated with 
an increased risk of surgery (OR = 1.76, 95%CI: 
1.24-2.51) and hospitalization (OR = 2.07, 95%CI: 
1.59-2.68) of IBD patients compared to those patients 
with sufficient levels of vitamin D[129].
The beneficial effect of vitamin D supplementation 
is connected with its immunomodulatory role in 
IBD. In IBD patients, vitamin D levels are strongly 
inversely correlated with intestinal inflammation[130]. 
Animal models have suggested that increased vitamin 
D intake prevents inflammation-associated colon 
cancer[53]. Additionally, supplementation with vitamin 
D and vitamin D plasma levels correlated with quality 
of life in UC and CD patients during the winter/spring 
period in central European countries[131].
A further typical complication of IBD is anemia. 
Some discrepancies in different reports are a result 
of two different anemia mechanisms (iron deficiency 
anemia and anemia of chronic diseases) and various 
cut-offs for diagnostic hemoglobin levels and other 
markers for anemia like ferritin, transferrin, or 
hepcidin[132]. Anemia is connected with deficits in iron, 
zinc, copper, folate, and vitamin B12. According to a 
recent review and meta-analysis of over 2000 patients 
data from European countries, the overall prevalence 
of anemia in IBD patients was 24% (95%CI: 18-31), 
and in 57% of cases, it was iron-deficiency anemia[133]. 
In the Canadian Manitoba IBD Cohort Study, iron 
deficiency was identified in 20% of adult CD patients 
and 27% of UC patients, but anemia was diagnosed 
only in one third of these patients[134]. Iron and zinc 
plasma concentrations were also significantly lower in 
children with newly diagnosed IBD[135]. A newer study 
confirmed these data. Zinc deficiency in children with 
IBD is relatively common - affecting 40% of patients 
- especially when compared to deficiency in a healthy, 
age matched population (19%)[136]. In adults, higher 
zinc as well as lower serum levels were observed in CU 
patients as compared to controls[137,138]. Selenium is 
another micronutrient with antioxidant properties, but 
it did not differ in IBD children compared to healthy 
controls[135]. In adults, the concentration of selenium 
was significantly lower in UC patients than controls[138]. 
Surprisingly, the mean serum concentration of 
copper was higher in CD children compared with age-
matched patients suffering from UC or controls[139]. In 
adults, both CD and UC patients had higher levels of 
copper than controls[137]. No gender differences were 
observed, but men with pancolitis had significantly 
higher copper levels than men with proctitis.
A Brazilian study established vitamin B12 deficiency 
in 6% of patients in an IBD population (equally in CD 
and UC patients)[140]. Another study found vitamin 
B12 deficiency limited to CD patients with significant 
(over 20 cm) ileal resection[141]. In addition, folate 
concentration was not different between IBD children 
and adults when compared to age matched control 
groups[135,142]. Vitamin A deficiency in an American study 
was found in 16% of pediatric patients with IBD, while 
vitamin E deficiency in the same study was rare (5%), 
similar to the index in the healthy population (8%)[136]. 
Another study found no differences in mean vitamin A 
and E concentration between IBD children and healthy 
controls[135]. Modulation of gastrointestinal microflora 
in IBD influenced the bioavailability of vitamin K. In a 
Polish pediatric population, the prevalence of vitamin K 
deficiency was 54.0% in CD and 43.7% in UC. Vitamin 
K status in this study was assessed indirectly using 
determination of a protein induced by lack of vitamin 
K (PIVKA-Ⅱ)[143]. Single studies have analyzed other 
vitamins: 30% of adult IBD patients have vitamin B6 
deficiency, and a decrease in vitamin C levels was 
observed in adult IBD patients in remission[72,144].
In summary, nutrition is a key factor in IBD - it 
is involved in the pathogenesis and in the treatment 
of these diseases. Nutrition in IBD is still a challenge 
for patients and for medical care. Recent papers 
have shown that patients’ knowledge in this matter 
is relatively weak and needs improvement[145]. Fur-
thermore, the increasing number of children with IBD 
opens a new chapter in nutritional science. In these 
cases, nutrition must ensure proper development as 
well as promoting remission of the diseases. 
PARENTERAL NUTRITION IN IBD
Estimates suggest that 20%-85% of patients suffering 
from IBD are malnourished or underweight[4,138,146]. 
Malnutrition occurs more frequently in patients with 
CD than those with UC. There are several reasons 
why patients with IBD are malnourished, and they 
are mostly related to the significant importance of the 
small bowel condition in patient body weight[147].
The relationship between metabolic condition and 
IBD is complex. Nutritional therapy is carried out 
through the combination of EN and PN (Figure 2). 
Moreover, nutritional treatment can be divided into 
primary and support therapy. The aim of primary 
therapy is to induce and maintain remission, and 
support therapy aims to enable the long-lasting effects 
of pharmacological treatment. 
Mode of action
PN can benefit patients with IBD as an alternative 
for enteral intake of proteins, fats, vitamins, and 
minerals. PN is used in patients with contraindications 
or EN intolerance, especially those with symptoms of 
severe malnutrition. TPN is also used during the acute 
inflammatory phase (obstruction, toxic megacolon, 
active fistulas), in the preoperative period, and in 
groups of patients with SBS due to previous extensive 
bowel resections[5,6].
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Induction therapy in active disease
PN is recommended for severely malnourished 
patients unable to take food spontaneously or by tube 
(nasogastric or nasoduodenal tube, gastrostomy). 
Severe malnutrition is defined as a loss of more than 
5% of body mass during 1 mo or 10% in 6 mo and 
body mass index (BMI) less than 19 kg/m2[146]. An 
accompanying marker of malnutrition is low serum 
albumin level, which often correlates with the acute 
phase and poor prognosis. 
Proper restitution of nutritional state ought to be 
considered, especially in pediatric patients. IBD by 
itself or in combination with the effects of medication 
(steroids) can severely impair normal growth and 
development, sometimes with definitive deterioration 
of children’s condition. A combination of under-nutrition 
and growth failure is typical for pediatric patients 
with IBD, although nutritional disturbances are more 
common in children with CD compared with those with 
UC. IBD therapy of adult patients mostly concentrates 
on inducing and maintaining remission through EN. In 
children, improvement of nutritional status and thereby 
restoration of somatic and psychological condition 
needs to be one of the main goals of therapy, achieved 
in severe cases only with the introduction of PN[148].
Thus, PN as TPN or supportive therapy is particularly 
indicated in the preoperative period in severely mal-
nourished patients for the restitution or improvement 
of their metabolic condition. Expected benefits are 
improved wound healing, prevention of postopera-
tive complications (anastomotic leaks), and limited 
perioperative weight loss. There are studies strongly 
indicating a correlation between low preoperative serum 
albumin level and higher risk of poor mucosal healing 
or anastomotic leak[149,150]. In the early postopera-
tive period, TPN provides full calorific, electrolyte, 
microelement, vitamin, and fluid requirements. In 
addition, when there are complications in the course 
of IBD or during the postoperative period, such as 
bowel obstruction, fistula, or toxic megacolon, PN is the 
main route for metabolic support. Combined feeding is 
indicated as early as possible postoperatively, and EN 
combined with PN diminishes inflammation and induces 
remission. It also can improve mucosal healing by its 
local immune-stimulating effects[151]. The duration of 
PN during perioperative periods depends on the type of 
surgery and the patient’s condition. In patients with CD 
and multiple small bowel resections resulting in SBS, PN 
is indicated as a prolonged supportive therapy[146].
In fact, the available data show that while PN 
seems to play a primary role in the management of 
patients with active CD, it does not have a primary 
therapeutic effect in active UC and does not induce 
clinical remission of this type of IBD. The use of 
artificial nutrition in the treatment of active CD 
is mostly based on the theoretical background of 
temporary bowel rest, decreasing motoric function, 
and thus antigenic stimulation by food components, 
leading to increased bowel permeability. Coincident 
metabolic support allows patients to restitute their 
metabolic status with better and faster intestinal cell 
renewal and better mucosal healing[152]. 
To date, few controlled clinical trials have been 
conducted to show the effect of TPN on inducing 
remission in active CD. Three months after starting PN, 
the remission rate varied between 20% and 80%[153]. 
In other reports, authors found the effectiveness of 
fistula healing during TPN improved from 43% to 
63% in patients linked with weight gain and metabolic 
restitution[154,155].
Moreover, the latest studies in adults have not 
shown a statistically significant decline in mortality in 
GI Function
Yes
Enteral nutrition
Exclusive Supplemental
Nasogastric/duodenal 
feeding tube or orally
If well tolerated - 
additional oral feeding
No
Parenteral nutrition
Partial Total
Peripheral 
i.v. route
Central 
i.v. route
If well tolerated -
additional enteral nutrition
Figure 2  Rules of nutritional therapy depended of normal function of gastrointestinal system. GI: Gastrointestinal.
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surgical patients with PN support in IBD, except for 
the severely malnourished[146,156]. There are no large 
randomized studies concentrating exclusively on the 
effects of PN in patients with IBD[146,157,158]. Thus, there 
are no data on PN support during the preoperative and 
perioperative period and disease relapse[159]. However, 
theory and clinical experience has strongly established 
PN as a supportive therapy, especially in children 
in the preoperative period or during perioperative 
complications.
Maintenance therapy in remission
PN seems to have a limited role as a maintenance 
therapy in remission. It may be indicated in some 
restricted cases, such as SBS after extensive bowel 
resection, bowel obstruction, high-output fistula, 
patients with severe dysmotility, and patients intolerant 
to EN[147]. For patients with SBS and limited absorption, 
PN is advocated for years until they reach maximal 
bowel adaptation (hyperplasia and bowel elongation 
and dilatation). Nevertheless, in some cases, PN must 
be considered as life-long therapy.
Bowel obstruction in the first 2 years after surgery 
has a frequency of around 15%, reaching 18% after 
10 years and 29% after 30 years[159]. Because each 
subsequent laparotomy/laparoscopy increases the risk 
of adhesions, conservative treatment is favored and 
recommended for as long as possible with the support 
of PN in cases of subileus, repeated incomplete 
bowel obstruction, and severe dysmotility. Similarly, 
in patients in remission with high-output jejuno/
ileostomy, PN plays a crucial role in metabolite and 
fluid supply. 
Long lasting PN increases the risk of complications 
related to metabolic disturbances, liver failure, 
cholestasis, central line infection, and catheter-related 
venous thrombosis, thus significantly impacting patient 
quality of life. If the gut can be used safely, EN is 
actually the preferred feeding method for IBD patients 
and must be the first choice in the induction and 
remission phase of treatment[147,160,161].
Side effects
Generally, PN is accomplished through central venous 
catheters (CVC) placed in central veins, mostly in 
the superior vena cava. There are special types of 
catheters for long-lasting intravenous therapy, and the 
access, especially in pediatric patients, is performed 
under general anesthesia. Because of the limited 
number of central veins, it is very important in IBD 
patients with a possibility of long-lasting PN to reserve 
central veins for nutritional access.
About 5%-15% of patients have complications 
related to central venous access. There are four main 
risks of PN: line infections, liver failure, metabolic 
disturbances, and vein thrombosis. Most PN are carried 
out at home as home parenteral nutrition (HPN) 
according to the “all-in-one” method, administered 
by the patient or by family members. Deviation from 
the correct method of PN administration may result in 
temporary serum glucose level disturbances, fluid and 
electrolyte imbalances, and hunger strikes. Patients 
on long-lasting PN are at a significantly increased risk 
for developing metabolic bone disease, and vitamin, 
microelement, and serum leptin disturbances[162-164].
Liver failure seems to be the most important 
complication, apart from septicemia, correlated with 
PN. Acute hepatic complications after the introduction 
of PN include liver dysfunction and cholestasis, 
painful hepatomegaly, and hyperammonemia. They 
can develop at any age but are most common 
among pediatric patients. PN-associated cholestasis 
is linked with the administration of soybean-based 
intravenous fat emulsion[165]. In adults, the most 
common complication is liver steatosis. Liver disease 
incidence is strictly related to HPN duration. Moreover, 
liver dysfunction may be transient, as evidenced 
by elevated transaminases, bilirubin, and alkaline 
phosphatase; and it commonly occurs when HPN is 
started. Delayed or persistent elevations may result 
from an excess of amino acids in the liquid nutritional 
mixture. In some patients progressive fibrosis of the 
liver may occasionally develop. Long-term TPN is 
also a well-documented factor for cholelithiasis, with 
frequency of about 40%[166,167].
CVC related septicemia and vein thrombosis are 
the most common complications leading to catheter 
replacement. The septicemia rate in the first 1000 d 
of HPN based on large group analysis ranged between 
12% to 0.5-0.6/1000 HPN days, with Staphylococcal 
septicemia being dominant[168-170]. A higher frequency 
was observed in the first 1000 HPN days, especially in 
pediatric patients. Pediatric patients were also more 
likely to need catheter replacement because of injury 
(disruption) and spontaneous removal more often. 
TPN is realized through continuous intravenous 
flow of fluids, which obviously influences quality of life. 
Compared to EN, PN generates much higher costs and 
very often requires professional nursing. New types of 
central line catheters inserted peripherally or without 
general anesthesia may partially improve patients’ 
quality of life[171].
In summary, PN is a significant element of treatment 
in the group of IBD patients, is often life-saving and 
should be implemented when required. However, 
there are no evidence-based guidelines relating to the 
effectiveness of PN in the therapy of IBD. Thus, EN 
should be re-introduced as soon as possible, being 
more suitable physiologically, safer, and less expensive.
ENTERAL NUTRITION IN IBD
For more than 40 years, enteral feeding has been 
used in the nutritional therapy of IBD. From the early 
1970s, when the first primary therapeutic effects of 
an elemental diet in CD patients were shown, multiple 
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studies regarding EN were carried out. The observed 
therapeutic effect was different depending on the type 
of IBD (CD vs UC), the age of the patients, their clinical 
presentations, and their concomitant treatment[172].
Generally, EEN is the provision of 100% of a 
person’s nutritional requirements from a liquid nutri-
tional formula either orally or via a feeding tube. EEN 
is usually provided for 6-8 wk and then a normal diet 
is gradually reintroduced[173].
Protocols of EEN may be different regarding 
composition of the enteral formula and route of 
administration. Three main types of enteral formulas 
are used in EEN depending on the degree of protein 
hydrolysis. Polymeric formulas are designed to 
mimic the general diet with non-hydrolyzed proteins, 
carbohydrates, and fat. The source of protein is 
usually casein, carbohydrates are provided as corn 
maltodextrin, while the source of fat is canola or 
soybean. Semi-elemental and elemental formulas are 
planned for use in patients with malabsorption, so the 
nutrients are partially (semi elemental formulas) or fully 
hydrolyzed (elemental formulas). Protein is usually in 
the form of dipeptides or tripeptides in semi elemental 
formulas and free amino acids in elemental ones. 
Carbohydrates are supplied as hydrolyzed cornstarch, 
maltodextrin, or fructose, and lipids as fatty acids 
esters or medium-chain triglycerides[174]. Additionally, 
diet may be of standard concentration (1 kcal/mL) or 
high concentration (2 kcal/mL). Depending on the fat 
concentration, very low fat diets (< 3 g/1000 kcal), low 
fat diets (< 20 g/1000 kcal), and high fat diets (> 20 
g/1000 kcal) may be distinguished[3].
In the majority of early clinical studies with EEN, 
elemental formulas were used[175]. Nevertheless, the 
latest clinical studies showed that polymeric formulas 
were as effective as elemental formulas at inducing 
disease remission both in children and adults[172,176].
Mode of action 
The mechanism underlying the therapeutic response to 
EEN still remains unclear. There are a few theories that 
try to explain its anti-inflammatory properties. Initially, 
low antigenic load was thought to be responsible 
for curative effects, but later studies showed that a 
polymeric diet was as effective as an elemental one 
in inducing remission in active CD[7]. Another theory 
indicated change of the profile of fatty acids in the 
enteral diet and its possible influence on bacterial 
microflora of the gastro-intestinal tract, resulting in the 
therapeutic effect on CD[8]. 
The latest studies have indicated downregulation 
of mucosal pro-inflammatory cytokines as a possible 
factor responsible for inducing remission in IBD[177,178]. 
One of the latest theories indicated a strong anti-
inflammatory effect of EN formulas on intestinal 
mucosa accompanied by histopathological healing. 
EN formulas enriched with tumor growth factor beta 
(TGF-β) induced clinical remission of CD. This was 
associated with mucosal healing and a decrease 
in pro-inflammatory cytokines, such as IL-1, IL-8 
and interferon gamma, in mucosal specimens of 
the terminal ileum and colon; and an increase of 
TGF-β in the terminal ileum. This suggested that 
clinical remission of CD during EEN is rather a result 
of a reduction of the inflammatory process than 
an improvement in the nutritional status of the 
patient[179]. Another clinical study showed that the anti-
inflammatory effect of EEN preceded the nutritional 
effect and was maintained until the end of the 
study[180]. The specific diet used in this study contained 
TGF-β, which was postulated as the therapeutic 
activity of the formula used[177]. This observation was 
confirmed in a retrospective pediatric study, where the 
authors reported more effective results in decreasing 
clinical activity of CD and improving nutritional status 
of patients after EEN with polymeric formula enriched 
with TGF-β2 when compared with patients fed with 
non-TGF-β2 enriched formula[181]. Moreover, a recently 
published prospective study on a pediatric population 
showed a correlation of daily protein and calorie 
intake during EEN with both clinical response and the 
concentration of TGF-β1 in CD children, confirming a 
potential role of TGF-β in the stimulation of healing 
processes in IBD[182]. Additionally, the time needed for 
clinical response in CD children treated with EEN was 
comparable when using TGF-β enriched formulas and 
formulas stimulating TGF-β release[181-183].
Overall, no single component of EN has been 
defined as explaining the curative effect of this 
therapy. Nevertheless, some components of EN, such 
as glutamine, arginine, and polyunsaturated fatty 
acids, were shown to have beneficial properties in IBD 
patients[184]. 
Despite the fact that some experimental and 
clinical studies showed a positive effect of arginine 
and glutamine on clinical symptoms and inflammatory 
mediators in different inflammatory diseases, including 
CD, their role in IBD is poorly documented[185,186]. 
Although early studies showed an improvement in 
the clinical course of diseases after arginine-enriched 
formulas were used in EN, the latest meta-analyses 
did not confirm these findings[187,188]. Additionally, a 
glutamine-enriched enteral diet was not confirmed 
to be superior to a standard polymeric diet in the 
treatment of active CD patients[189]. Moreover, data 
from clinical studies on EN in critically ill patients 
showed conflicting results. In some groups of patients, 
increased mortality was observed after glutamine-
enriched EN[174]. Based on these results, the latest 
European Society for Parenteral and Enteral Nutrition 
(ESPEN) guidelines did not recommend the use of 
immune mediating nutrients in EN[190].
Several recent studies have shown that EEN 
strongly influenced the physical and biochemical 
characteristics of stool, especially sulfide and butyric 
acid concentration[191]. Changes in stool metabolic 
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activities interact with gut microbiome composition, 
which may be also connected with the curative 
properties of EEN[192].
The role of invasive bacterial species as triggers 
and coinfection factors in IBD has not been fully 
identified. Recent studies reported an increased 
prevalence of MAP and adherent-invasive Escherichia 
coli in intestinal tissues, stool cultures, and blood of 
CD and UC patients, especially in the active stage 
of disease[49]. EEN may influence invasive bacterial 
species and decrease their prevalence through 
modification of bacterial diversity and modulation 
of predominant intestinal bacterial microflora. This 
may also be a potential mode of action of nutritional 
therapy in IBD[193,194].
Induction therapy in active disease
EEN is an effective treatment option for children and 
adolescents with IBD, currently recommended as the 
first line of the therapy in active CD[195]. Nevertheless, 
latest evidence suggests that this therapy may be 
more effective in children than in adults, especially in 
CD compared with UC[196,197]. Additionally, nutritional 
support is beneficial for the development and pre-
vention of growth retardation, which is a frequent 
clinical symptom in children with IBD, especially with 
CD. A Cochrane systematic review confirmed the 
positive therapeutic role of EEN on development and 
growth parameters in children with CD. Moreover, 
children treated with EEN avoided corticosteroid 
therapy and steroid-dependent adverse effects during 
the first year after IBD diagnosis[191]. In many pediatric 
IBD centers in Europe, EEN therapy is frequently 
chosen as the primary induction therapy in CD. In 
contrast, in North America, only a few centers prefer 
EEN in newly diagnosed CD children[198]. The British 
Society of Gastroenterology guidelines suggest EEN 
as the first line therapy in children and adolescents, 
especially in those with small bowel involvement in 
CD[9]. Additionally, case reports of three children with 
newly diagnosed perianal CD found that combined 
EEN with pharmacological and surgical therapy may 
be effective as an induction treatment resulting in the 
remission of perianal CD lesions[199].
EN as induction therapy was confirmed as being 
most effective when it was administered as EEN via 
nasogastric tube excluding a normal diet[200]. Recently, 
however, a retrospective study analyzing the efficiency 
of a fractionated oral diet compared to continuous EEN 
in children with CD was published. The authors found 
comparable clinical efficacy of the treatment in both 
groups of patients, except for weight gain, which was 
higher in the continuous feeding group. Additionally, 
they did not observe intolerance of the volume of the 
nutrient administered orally that had been observed in 
previous studies[201,202]. 
The first studies on EEN, both for polymeric and 
elemental diets, as primary nutrition therapy in adult 
CD patients showed a therapeutic effect that was as 
strong as steroid therapy in inducing clinical remission. 
However, a later Cochrane systematic review showed 
that steroid therapy is more effective than EEN in 
adults[176]. When taking into consideration the potential 
adverse effects of both methods of treatment, EN is a 
much safer method of treatment and is still used as a 
therapeutic method.
Nevertheless, in different parts of the world 
there are different, sometimes contradictory, rules 
regarding the place of EEN in management of IBD. 
Currently, EEN is recommended as the first line of the 
therapy in active CD in adults, when treatment with 
corticosteroids is not feasible[195]. Recent European 
and North American clinical guidelines recommend 
EEN as a therapeutic option only if a patient declines 
pharmacological therapy or as an adjunctive treatment 
to support nutritional status rather than as primary 
treatment[203,204]. 
The British Society of Gastroenterology guidelines 
suggest EEN in adult patients in preference to steroids, 
immunosuppressants, or surgery, especially in patients 
non-responsive to 5-aminosalicylic acid (5-ASA) or 
with contraindications to steroid therapy[9]. In contrast, 
in Japan, EEN is still used in adult patients with IBD as 
the preferred first line therapy[205].
It is not currently known why the benefits of EEN 
therapy achieved in children are not demonstrated in 
adults. One of the reasons may be that EEN therapy 
induces remission of the disease by reducing mucosal 
inflammation. In adult IBD patients, who have a longer 
disease course and more frequent complications, which 
are often not connected with inflammatory status, EEN 
may be less effective.
There is limited evidence suggesting that EEN 
therapy is more effective in newly diagnosed CD 
patients compared to patients with long-standing 
CD. In an Australian study in CD children, induction 
treatment with EEN was successful in 80% of newly 
diagnosed and 58% of long-standing CD patients[206]. 
Another pediatric study confirmed these results, 
showing a higher relapse rate after the second course 
of EEN (70%) when compared to the first one (67%) 
during a 1 year period of follow-up[207]. 
However, a different treatment response dependent 
on the time since diagnosis is not only demonstrated 
for EEN therapy. Similarly, response and remission 
rates achieved after anti-TNF therapy were higher 
in CD children than in adults, which could be related 
to disease duration prior to starting treatment[208]. 
Nevertheless, a recent small study was published that 
did not confirm these observations. In a group of 22 
patients with CD, the authors found that EEN was as 
effective in newly diagnosed patients as in those with 
existing disease[172]. 
Additionally, a large retrospective Chinese study 
showed that CD patients who completed EEN 
therapy before surgical treatment of CD had a lower 
Wędrychowicz A et al . Advances in nutritional therapy in IBD
1057 January 21, 2016|Volume 22|Issue 3|WJG|www.wjgnet.com
risk of complications and reoperations and longer 
immunosuppressant-free intervals when compared to 
patients without EEN therapy[209].
Maintenance therapy in remission
Different nutritional strategies can be considered in 
maintenance therapy during remission. Two alternatives 
are cyclical EEN, including nocturnal infusions of enteral 
diet during one of every 4 mo or supplementary EN 
with unrestricted daytime diet[210].
Children who continued supplementary EN through 
a nasogastric tube after finishing induction therapy 
remained in remission for a longer period of time. A 
retrospective Scottish study in pediatric patients who, 
after induction of CD remission, used EEN therapy 
with continued maintenance EN with 25% of their 
earlier EEN volume showed remission rates after 1 
year of 60% compared to 65% in patients undergoing 
azathioprine treatment (p = 0.14) and 15% in patients 
with no treatment (p = 0.001)[211].
In a Japanese randomized controlled trial com-
paring immunosuppressive therapy and elemental diet 
as a maintenance therapy in adult CD patients, the 
authors found a higher remission rate after 2 years 
of follow-up in a 6-mercaptopurine treated group 
(56.7%) and an elemental diet treated group (46.9%) 
compared to a group without maintenance treatment 
(21.2%)[212]. However, in this study, the majority of 
patients drank elemental EN orally for a 2 year period. 
This may be difficult to achieve in other populations, 
especially in pediatric ones.
Another Japanese randomized controlled trial in 
adult CD patients compared maintenance enteral 
therapy supplying 50% of nutritional requirements 
with unrestricted diet without any supplementation. 
The study showed a lower relapse rate after 2 years of 
follow-up in the elemental diet group (35%) compared 
to the free unrestricted diet group (64%)[213].
Moreover, continuation of EN maintenance feeding 
before completion of puberty was associated with 
improved linear growth of children[210]. EEN was 
also effective in children with perianal CD disease in 
maintenance remission of lesions[199].
Two pediatric retrospective studies showed that 
only 31% of children who achieved remission after 
an EEN course continue EN as maintenance therapy, 
with a mean time of 10 mo (range, 4-12 mo and 1-15 
mo)[206,211].
Thus, poor compliance in maintenance EN therapy, 
secondary to taste fatigue, may be a main factor 
limiting the length of EN supplementation and the 
efficacy of this method of treatment.
Side effects
EN is an effective therapy option without severe 
adverse effects. Some minor side effects may occur 
during administration of a nasogastric tube, such 
as nausea and vomiting, but they usually disappear 
quickly[4]. If the volume of formula is increased gra-
dually, it should be better tolerated by the patient. 
Nevertheless, some patients can better tolerate the 
prescribed volume at the beginning of the EEN course, 
hoping for induction of the remission of the disease, 
but if the disease symptoms are still present, the 
compliance rate may be lower than expected[214]. From 
the patient’s point of view, a very important side effect 
of the EEN regime is the restriction of the possibility 
of eating and drinking additional food, which may 
seriously limit compliance with the diet[4]. 
Both in pediatric and adult studies, some patients 
did not accept the EEN regimen at all and refused EEN 
treatment. In addition, some patients did not comply 
with the EEN regime during nutritional therapy, due to 
eating additional food to the prescribed formulas[214,215]. 
This observation also requires attention, because it 
reduces compliance of the patients and limits the 
efficacy of EEN.
Quality of life
Elemental formulas compared to polymeric ones have 
a distinctive smell and flavor due to a higher level of 
hydrolysis, mainly because of the presence of amino 
acids, which causes them to be poorly tolerated by 
patients when they are administered orally[216].
Bitterness, offensive smell, and belching and hiccup 
may considerably impair patients’ quality of life and 
compliance during EN with the elemental formula. 
Modification of the formula by changing the particle 
size of branched-chain amino acids reduced these 
symptoms and increased patient compliance[217]. 
Moreover, some additive flavors, such as apple, 
pineapple, and fruit flavors, increased sweetness and 
sourness and masked the bitterness of the formula[217].
 The mode of delivery of the formula is very 
important for patient quality of life and compliance. 
Many studies with high compliance rates administered 
elemental formulas via nasogastric tubes rather than 
orally. Because this method of administration need 
patients’ compliance and impairs the quality of life, it 
is better accepted by hospitalized patients. However, 
for outpatients taking the formula orally may be more 
socially acceptable. 
The influence of EEN on health-related quality 
of life was confirmed in clinical trials. In a Japanese 
randomized, controlled trial, the authors did not show 
significant differences between semi-elemental diet fed 
and normal diet fed groups[218]. However, another trial 
confirmed a significant improvement in health-related 
quality of life after EEN treatment in children with 
active CD[219]. Additionally, in this prospective cohort 
study, a weak correlation between mucosal healing 
after EEN therapy and quality of life was shown, 
although the majority of patients had high scores on 
quality of life questionnaires[219].
Interesting data were reported in a Chinese 
clinical trial with adult active CD patients treated 
with EEN for 4 wk. The enteral feeding protocol 
used in this study included multiple low doses of 
Wędrychowicz A et al . Advances in nutritional therapy in IBD
1058 January 21, 2016|Volume 22|Issue 3|WJG|www.wjgnet.com
oral polymeric EN formula in the daytime and a self-
intubated nasogastric tube feeding at night for 4 wk. 
Patients who achieved remission also had significantly 
improved total IBD quality of life scores, intestinal and 
systemic symptoms, and emotional and social scores. 
In addition, 61.5% of patients who achieved remission 
after the EEN course wanted to repeat the EEN course 
if the disease would relapse again[220]. These data 
showed that the positive impact of EEN on disease-
related quality of life symptoms exceeded its negative 
influence and limitations related to the method of 
feeding.
Short-term and long-term outcomes of nutritional 
therapy
In a retrospective study concerning the therapeutic 
efficacy of EEN with three different enteral diets 
(polymeric, semi-elemental, and elemental) when 
compared to corticosteroid therapy, the authors 
observed a higher remission rate (80% vs 30%) after 
12 mo of follow-up, comparable for all three formulas. 
Additionally, a higher number of patients treated 
with EEN achieved endoscopic and histopathological 
remission after 8 wk of treatment[221]. Another retro-
spective study on a population of newly diagnosed 
CD children showed that more than 90% of patients 
treated with EEN achieved remission after a median 
time of 6 wk[222]. Moreover, 47% of patients treated 
with EEN avoided corticosteroid therapy for the next 
1-7 years[223]. According to a recently published meta-
analysis, concerning five randomized controlled trials 
on newly diagnosed pediatric CD patients (total n = 
147), EEN efficacy was comparable to corticosteroid 
therapy, with equal rates of clinical remission[224]. A 
second meta-analysis of children with CD, based on 
the results of four randomized controlled trails (total 
n = 144), also found no significant differences in 
the remission rates between EEN and corticosteroid 
therapy[225]. The large retrospective study regarding 
short-term follow-up of children after 8 wk of EEN 
confirmed earlier observations. Additionally, during 
2 years of follow-up the patients’ weight and BMI 
Z scores significantly improved when compared to 
baseline. However, EEN course increased height 
velocity during 6 mo in responding patients but did 
not improve height Z score in a 2 year term of follow-
up[226]. Overall, 57% of patients relapsed during 
the next 2 years with a median relapse time of 6.5 
mo. Nevertheless, 70% of them responded to a 
second course of EEN that was used as an induction 
treatment[227].
In a Canadian pediatric study on newly diagnosed 
CD children, similar remission rates (89% vs 91.3%, p 
= NS) after 3 mo and similar relapse rates (40.6% vs 
28.6%, p = NS) after 12 mo of follow-up in the EEN 
and corticosteroid groups were reported[226]. Similar 
observations were presented in an Australian pediatric 
study during 2 years of follow-up[227].
In a large Dutch pediatric study, assessing a 6 wk 
EEN course in active CD children, 71% of patients 
achieved complete remission and 26% partial 
remission of disease. The median time observed to 
relapse of CD was 21 wk (range, 2-169 wk), while 
after a median follow-up time of 18 mo 62% of 
patients had a relapse of CD. Additionally, Kaplan-
Meier analysis showed that the cumulative risk of 
relapse within the first year of follow-up after EEN 
induction therapy was 59%[214].
Future perspectives for nutritional therapy
Based on the latest research data, numerous new 
questions will be asked regarding the influence of 
nutrition on the pathogenesis of IBD and its methods 
of application, especially in EEN.
A role for nutritional factors in “IBD integrome” theory 
is still not quite clear[228]. Detailed potential interactions 
among nutrition and the genome, microbiome, and 
immunome may have important clinical value and need 
to be investigated in future studies.
The confirmed influence of EEN on bacterial 
microflora modification provokes the question whether 
the enrichment of enteral diet with prebiotics or 
probiotics increase the EN efficacy in IBD. 
Taking into consideration the potential side effects 
of EN, we also should ask the question whether EEN 
manner is mandatory for therapeutic effect, or whether 
for better patient quality of life we should propose 
semi-exclusive nutrition.
Furthermore, if changes in the fatty acid profile in 
an EN diet may result in anti-inflammatory activity, 
what other diet supplements or fat modifiers may 
show similar or even stronger therapeutic effects?
Future studies also should specify the indications 
for different ways of feeding (parenteral vs enteral, 
tube vs oral) and the precise details of nutritional 
protocols (time, type of formula, and dose). Finally, 
increasing patient compliance during nutritional 
therapy is essential to establish the optimal formula 
composition regarding its smell and taste. 
Answers to the above questions will take nutrition 
therapy a step further and increase the efficacy of 
treatment and its tolerance by both adult and pediatric 
patients.
CONCLUSION
In summary, the role of nutrition in IBD is essential, it is 
involved both in pathogenesis and in treatment of these 
diseases. Although research studies have confirmed 
its effectiveness in induction and maintenance therapy, 
outcomes from actual use in children and adult patients 
with IBD in different countries is not the same. EEN is 
the first-line therapy option in active CD in children and 
to a lesser degree in adult patients, while PN should 
only be considered as an alternative method of nutrition 
for those with EN intolerance or during perioperative 
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periods of treatment. Future improvements in nutritional 
protocols and ameliorating the side effects of currently 
used nutritional therapy and improving the quality of 
life of the patients would result in better acceptance and 
better tolerance of this method of treatment by IBD 
patients.
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